



IT IS NOT A FAD. IT IS AT THE CORE OF WHO WE

For more than 135 years, Eli Lilly and Company has shown its commitment to be a responsible global citizen -- in large part, through a long history of philanthropic contributions. Today, our understanding of corporate responsibility is evolving beyond charity and reaching into the core of our business operations. We're drawing on our scientific, technical and business expertise to meet the needs of patients and communities, while reducing our environmental footprint.

We also work to improve global health by helping expand access to medicines, by working to strengthen policies that foster better health, by providing help to those in need, and by being an active participant in the communities we serve.

We consider the following corporate responsibility issues to be among the most important to our core business:

- The development and production of safe and effective medicines,
- Upholding ethical standards in business practice, research and development, and marketing,
- Addressing issues of access to medicines and affordability,
- Maintaining a diverse and engaged global workforce, and
- Minimizing environmental impacts and waste.

We believe that collaborating with governments and other stakeholders builds trust and reinforces our mutual interest in bringing value to patients and society. And we know that conducting our business responsibly enables us to attract a principled, passionate, and creative workforce—individuals who seek to contribute their talents to our mission of improving global health.

LILLY'S GLOBAL DAY OF SERVICE

At Lilly, we're committed to being a leader in corporate responsibility, which includes being an active participant in the communities we serve. We have a robust history of community involvement and believe we can make an impact that extends far beyond the medicines we make.

Each October, about 20,000 Lilly employees spend a day out of the office, helping friends and neighbors in communities around the world. Since the program launched in 2008, employees in more than 40 countries have given nearly 500,000 hours through Global Day of Service initiatives, making it one of the largest single-day volunteer programs in the world. In India we partner with local Non Governmental Organizations to contribute in a meaningful manner. Employees across India work with local organizations to make a difference in the lives of the people who are under privileged.



“A growing body of evidence demonstrates that when a company engages with partners in an area in which the company has deep expertise and a vested interest, society benefits and the company enhances its own performance.”

John Lechleiter

Ph.D., Lilly chairman, president and chief executive officer





ARE

GLOBAL HEALTH PROGRAMS

Health is one of our most important personal assets and medicines play an essential role in preserving it. Yet around the world, millions lack access to comprehensive health care, including medicines and other treatment tools. Lilly is committed to expanding access to medicines, and we work with partners to improve health outcomes for underserved populations.

In 2011, we launched a new platform to help address the issues, The Lilly Global Health Innovation Campaign. The campaign encompasses two of Lilly's signature public/private programs, The Lilly NCD Partnership and The Lilly MDR-TB Partnership.

Tuberculosis (TB), often thought of as a disease of the past, continues to plague the world's most vulnerable populations. In sheer numbers, Asia bears the brunt of the epidemic. Almost 50% of multidrug-resistant TB (MDR-TB) cases worldwide are estimated to occur in India and China. These dire statistics are even more dismal considering that TB and MDR-TB are treatable and curable.

Recognizing that MDR-TB cannot be halted by medicine alone, in 2003, Eli Lilly and Company officially created The Lilly MDR-TB Partnership. This public-private initiative mobilized over 25 partners on five continents to tackle the scourge of TB and MDR-TB head on. Lilly contributed US\$ 120 million in cash, medicines, advocacy tools and technology to focus global resources on prevention, diagnosis and treatment of patients with MDR-TB; and an additional US\$ 15 million to the Lilly TB Drug Discovery Initiative to accelerate the discovery of new drugs to treat TB. The company made this investment to ensure that thousands of MDR-TB patients receive the care and medication they need to combat this disease.

The third phase of the Lilly MDR-TB Partnership supported by Lilly Foundation will be topically focused on:

- Providing training for healthcare providers, from professional health-care workers such as nurses and doctors, to informal care givers such as community volunteers.
- Improving supply and access to safe, effective, and high-quality second line drugs. Less than one percent of estimated MDR-TB patients globally receive appropriate second line treatment.

We will work with Governments and partners at the global and local level, with a specific focus on the four countries carrying the highest burden of MDR-TB: China, India, Russia and South Africa.

Lilly has also launched its signature initiative on Non-communicable Disease (NCD). The Partnership aims to address the growing global threat of non-communicable disease. It will identify models of care that increase treatment access and improve patient outcomes for underserved people, share what we learned with the global health community and advocate for successful solutions to be adopted and replicated around the world. India is one among the four countries where Lilly is partnering with leading Institutions of the country apart from Mexico, Brazil and South Africa. In India Lilly is partnering with Public Health Foundation of India (PHFI), Population Services International (PSI) and Project Hope to develop a comprehensive care model for management of Diabetes.

the *Lilly*
MDR-TB
partnership

For more information about The Lilly MDR-TB Partnership, please visit www.LillyMDR-TB.com
©2011 Eli Lilly and Company, Photo courtesy: Eli Lilly and Company

**Eli Lilly and Co.
(India) Pvt. Ltd.**

Plot No.92, Sector 32
Gurgaon Haryana INDIA
www.lillyindia.co.in